MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presentations during the 69th Scientific Sessions of the American Diabetes Association (ADA), being held from June 5-9, 2009 in New Orleans, Louisiana. Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 diabetes. Data from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of a year-long phase 2 diabetic study, DM-230, demonstrate that weight loss with Qnexa can significantly lower blood sugar in type 2 diabetics.
"Obesity and type 2 diabetes, which are inextricably linked, are growing at epidemic proportions worldwide and physicians need new, more effective treatment options for the millions of patients at risk," commented Leland Wilson, president and chief executive officer of VIVUS. "In clinical studies to date, Qnexa has demonstrated significant impact on patients' weight, glucose levels, HbA1c and other critical cardiovascular risk factors, in patients with and without diabetes. We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been selected for podium presentations at the ADA annual meeting."
Details for the two oral podium presentations of Qnexa data follow:
Date and Time: Saturday, June 6, 2009, 4:00-6:00 P.M.
Session: Novel Diabetes Treatments in Development in Humans
Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects
Location: Louisiane C, Morial Convention Center
Presenter: Louis J. Aronne, MD
Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.
Session: New Treatments in Development
Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss
Location: Hall E-2, Morial Convention Center
Presenter: W. Timothy Garvey, MD
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.
VIVUS, Inc. Timothy E. Morris Chief Financial Officer 650-934-5200 Investor Relations: The Trout Group Brian Korb 646-378-2923 Public Relations: Pure Communications, Inc. Jennifer Torres 312-624-9802
|SOURCE VIVUS, Inc.|
Copyright©2009 PR Newswire.
All rights reserved